Marilyn M Li

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4432225/publications.pdf

Version: 2024-02-01

68 papers	2,690 citations	331670 21 h-index	197818 49 g-index
75 all docs	75 docs citations	75 times ranked	5405 citing authors

#	Article	IF	Citations
1	Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. Neuro-Oncology, 2023, 25, 199-210.	1.2	6
2	Laboratory and Clinical Implications of Incidental and Secondary Germline Findings During Tumor Testing. Archives of Pathology and Laboratory Medicine, 2022, 146, 70-77.	2.5	11
3	Mammary-type Myofibroblastoma with Leiomyomatous Differentiation: A Rare Variant with Potential Pitfalls. International Journal of Surgical Pathology, 2022, 30, 200-206.	0.8	2
4	KMT2Aâ€MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8â€year followâ€up. Pediatric Blood and Cancer, 2022, 69, e29344.	1.5	1
5	Atypical teratoid rhabdoid tumor in a child with neurofibromatosis type 2: A novel dual diagnosis. Cancer Genetics, 2022, 262-263, 1-4.	0.4	2
6	Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers. Journal of Clinical Oncology, 2022, 40, 1081-1090.	1.6	36
7	Tiered Somatic Variant Classification Adoption Has Increased Worldwide With Some Practice Differences Based on Location and Institutional Setting. Archives of Pathology and Laboratory Medicine, 2022, 146, 822-832.	2.5	3
8	Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia. Haematologica, 2022, 107, 1746-1757.	3.5	14
9	Neuroblastoma and cutaneous angiosarcoma in a child with PTEN hamartoma tumor syndrome. Pediatric Blood and Cancer, 2022, 69, e29656.	1.5	1
10	A Novel TP53 Tandem Duplication in a Child with Li-Fraumeni Syndrome. Journal of Physical Education and Sports Management, 2022, , mcs.a006181.	1.2	2
11	Standardized evidence-based approach for assessment of oncogenic and clinical significance of NTRK fusions. Cancer Genetics, 2022, 264-265, 50-59.	0.4	5
12	CancerVar: An artificial intelligenceâ€“empowered platform for clinical interpretation of somatic mutations in cancer. Science Advances, 2022, 8, eabj1624.	10.3	14
13	Novel ATXN1/ATXN1L::NUTM2A fusions identified in aggressive infant sarcomas with gene expression and methylation patterns similar to CIC-rearranged sarcoma. Acta Neuropathologica Communications, 2022, 10, .	5.2	4
14	AACR Project GENIE: 100,000 Cases and Beyond. Cancer Discovery, 2022, 12, 2044-2057.	9.4	27
15	Congenital tumors of the central nervous system: an institutional review of 64 cases with emphasis on tumors with unique histologic and molecular characteristics. Brain Pathology, 2021, 31, 45-60.	4.1	15
16	Genomic characterization of a PPP1CB-ALK fusion with fusion gene amplification in a congenital glioblastoma. Cancer Genetics, 2021, 252-253, 37-42.	0.4	6
17	Application of Next Generation Sequencing in Laboratory Medicine. Annals of Laboratory Medicine, 2021, 41, 25-43.	2.5	99
18	NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome. JCO Precision Oncology, 2021, 1, 204-214.	3.0	36

#	Article	IF	Citations
19	BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers. Pediatric Blood and Cancer, 2021, 68, e28933.	1.5	9
20	Clinical impact of genomic characterization of 15 patients with acute megakaryoblastic leukemiaâ€“related malignancies. Journal of Physical Education and Sports Management, 2021, 7, a005975.	1.2	7
21	Mesenchymal PLAG1 Tumor With PCMTD1-PLAG1 Fusion in an Infant. American Journal of Dermatopathology, 2021, Publish Ahead of Print, 54-57.	0.6	2
22	Abstract 449: A standard operating procedure for the curation of gene fusions. , 2021, , .		0
23	The spectrum of rare central nervous system (CNS) tumors with EWSR1â€non‐ETS fusions: experience from three pediatric institutions with review of the literature. Brain Pathology, 2021, 31, 70-83.	4.1	29
24	The oncogenic roles of NTRK fusions and methods of molecular diagnosis. Cancer Genetics, 2021, 258-259, 110-119.	0.4	5
25	Recommendations for future extensions to the HGNC gene fusion nomenclature. Leukemia, 2021, 35, 3611-3612.	7.2	1
26	A Novel FBXO45-Gef-H1 Axis Controls Oncogenic Signaling in B-Cell Lymphoma. Blood, 2021, 138, 711-711.	1.4	1
27	Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer, 2020, 139, 60-67.	2.0	88
28	Using Machine Learning to Identify True Somatic Variants from Next-Generation Sequencing. Clinical Chemistry, 2020, 66, 239-246.	3.2	7
29	A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Research, 2020, 80, 3732-3744.	0.9	32
30	A Novel KMT2A-ARHGEF12 Fusion Gene Identified in a High-Grade B-cell Lymphoma. Cancer Genetics, 2020, 246-247, 41-43.	0.4	5
31	Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2020, 22, 1142-1148.	2.4	59
32	Evolution of histomorphologic, cytogenetic, and genetic abnormalities in an untreated patient with MIRAGE syndrome. Cancer Genetics, 2020, 245, 42-48.	0.4	7
33	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell, 2020, 37, 569-583.e5.	16.8	244
34	A germline PALB2 pathogenic variant identified in a pediatric high-grade glioma. Journal of Physical Education and Sports Management, 2020, 6, a005397.	1.2	2
35	Clinical significance of serial tumor next generation sequencing (NGS) in 155 pediatric cancer patients.. Journal of Clinical Oncology, 2020, 38, e13666-e13666.	1.6	1
36	Whole genome SNP arrays for best practice for detection of diagnostic, prognostic and therapy related copy number changes and copy neutral-loss of heterozygosity across solid tumors and hematologic malignancies.. Journal of Clinical Oncology, 2020, 38, e15575-e15575.	1.6	0

#	Article	IF	Citations
37	EPID-11. A MULTI-INSTITUTIONAL COMPARATIVE ANALYSIS OF THE CLINICAL, GENOMIC, AND SURVIVAL CHARACTERISTICS OF PEDIATRIC, YOUNG ADULT AND OLDER ADULT PATIENTS WITH IDH-MUTANT GLIOMA. Neuro-Oncology, 2020, 22, ii80-ii81.	1.2	1
38	Sclerosing Epithelioid Fibrosarcoma of the Bone With Rare EWSR1-CREB3L3 Translocation Driving Upregulation of the PI3K/mTOR Signaling Pathway. Pediatric and Developmental Pathology, 2019, 22, 594-598.	1.0	12
39	Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers. Journal of Molecular Diagnostics, 2019, 21, 873-883.	2.8	41
40	Genomic Analysis of Dysembryoplastic Neuroepithelial Tumor Spectrum Reveals a Diversity of Molecular Alterations Dysregulating the MAPK and PI3K/mTOR Pathways. Journal of Neuropathology and Experimental Neurology, 2019, 78, 1100-1111.	1.7	44
41	Variant Interpretation for Cancer (VIC): a computational tool for assessing clinical impacts of somatic variants. Genome Medicine, 2019, 11, 53.	8.2	36
42	Clinical utility of custom-designed NGS panel testing in pediatric tumors. Genome Medicine, 2019, 11, 32.	8.2	79
43	LGG-07. CLINICAL FEATURES OF NON-CANONICAL MOLECULAR DRIVERS IN PLGG; AN UPDATE FORM THE INTERNATIONAL PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii100-ii100.	1.2	0
44	LGG-14. THE GENETIC LANDSCAPE OF DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMORS. Neuro-Oncology, 2019, 21, ii102-ii102.	1.2	0
45	Pediatric Somatic Tumor Sequencing Identifies Underlying Cancer Predisposition. JCO Precision Oncology, 2019, 3, 1-26.	3.0	6
46	Effects of milrinone on inflammatory response-related gene expressions in cultured rat cardiomyocytes. Journal of Biomedical Research, 2019, 33, .	1.6	0
47	Authors' Reply. Journal of Molecular Diagnostics, 2018, 20, 125-126.	2.8	1
48	LGG-25. NOVEL FGFR2 FUSIONS DRIVE ONCOGENESIS VIA MAPK AND PI3K/mTOR PATHWAY ACTIVATION IN DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMORS. Neuro-Oncology, 2018, 20, i109-i110.	1.2	0
49	SETD2 mutations in primary central nervous system tumors. Acta Neuropathologica Communications, 2018, 6, 123.	5.2	27
50	Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure. Haematologica, 2018, 103, e427-e431.	3.5	56
51	Novel FGFR2-INA fusion identified in two low-grade mixed neuronal-glial tumors drives oncogenesis via MAPK and PI3K/mTOR pathway activation. Acta Neuropathologica, 2018, 136, 167-169.	7.7	20
52	Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next-Generation Sequencing Panel. Journal of Molecular Diagnostics, 2017, 19, 613-624.	2.8	36
53	Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway. Journal of Molecular Diagnostics, 2017, 19, 487-497.	2.8	33
54	Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. Journal of Molecular Diagnostics, 2017, 19, 4-23.	2.8	1,267

#	Article	IF	Citations
55	Clinical Impact of Genomic Information in Pediatric Leukemia. Frontiers in Pediatrics, 2017, 5, 263.	1.9	7
56	Effects of Epinephrine on Inflammation-Related Gene Expressions in Cultured Rat Cardiomyocytes. Translational Perioperative and Pain Medicine, 2017, 2, 13-19.	0.1	3
57	Effects of epinephrine on angiogenesis-related gene expressions in cultured rat cardiomyocytes. Journal of Biomedical Research, 2016, 30, 380.	1.6	4
58	Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome. Leukemia Research Reports, 2015, 4, 24-27.	0.4	17
59	Variation in pre-PCR processing of FFPE samples leads to discrepancies inBRAFandEGFRmutation detection: a diagnostic RING trial. Journal of Clinical Pathology, 2015, 68, 111-118.	2.0	34
60	p53 enables metabolic fitness and self-renewal of nephron progenitor cells. Development (Cambridge), 2015, 142, 1228-1241.	2.5	30
61	Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked. Experimental Hematology and Oncology, 2015, 4, 1.	5.0	8
62	A multicenter, cross-platform clinical validation study of cancer cytogenomic arrays. Cancer Genetics, 2015, 208, 525-536.	0.4	12
63	Identification of susceptibility loci in hereditary prostate cancer families using copy number variation and linkage analysis.. Journal of Clinical Oncology, 2015, 33, 232-232.	1.6	0
64	Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes. American Journal of Medical Genetics, Part A, 2014, 164, 2633-2637.	1.2	26
65	Using Cytogenetic Rearrangements for Cancer Prognosis and Treatment (Pharmacogenetics). Current Genetic Medicine Reports, 2013, 1, 99-112.	1.9	5
66	Clinical application of amplicon-based next-generation sequencing in cancer. Cancer Genetics, 2013, 206, 413-419.	0.4	98
67	The efficacy of targeted next-generation sequencing for detection of clinically actionable mutations in cancer.. Journal of Clinical Oncology, 2012, 30, 10598-10598.	1.6	0
68	Technical Standards and Guidelines for Use of Clinical Genomic Microarray Analysis in Hematopoietic and Other Neoplastic Disorders: A Draft From a Working Group of the American College of Medical Genetics Laboratory Quality Assurance Committee. Blood, 2011, 118, 4906-4906.	1.4	1